Prescribing optimal drug therapy for older people: Sending the right message

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 103-106

  Rochon, Paula A ^a   Anderson, Geoffrey M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DEMENTIA; DRUG SAFETY; ELDERLY CARE; HUMAN; NOTE; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; DRUG LABELING; HUMANS; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74549114172     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.473     Document Type: Note

References (19)

1. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864-1870.
2. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268(11):1417-1422.
3. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer. 1994;74(7)(suppl):2208-2214.
4. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329(7457):75.
5. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
6. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004;52(5):749-755.
7. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-1096.
8. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
9. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients [published correction appears in CMAJ. 2007;176(11):1613]. CMAJ. 2007;176(5):627-632.
10. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med. 2005;353 (22):2335-2341.
11. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
12. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220.
13. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438-446.
14. Food and Drug Administration. Risperdal (risperidone) Apr 2003. April 16, 2003. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm153478.htm. Accessed October 7, 2009.
15. Food and Drug Administration. Zyprexa (olanzapine) Mar 2004. March 2004. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm166542.htm. Accessed October 7, 2009.
16. Food and Drug Administration. Atypical antipsychotic drugs. April 11, 2005. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm150688.htm. Accessed October 7, 2009.
17. Food and Drug Administration. Antipsychotics, conventional and atypical. June 16, 2008. http://www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm110212.htm. Accessed October 7, 2009.
18. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf. 2006;15(6):369-386.
19. Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ. 2009;338:b217.